The trials showed an increase in interferon gamma (IFN-γ) and CSF eotaxins, which are associated with a slower cognitive decline in AD patients and a decrease in interleukin 6 (IL-6), which is associated with inflammatory states. The gene discussed is IFNG; the disease is Alzheimer disease.